Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
PTProtagonist Therapeutics, Inc. logo

Protagonist Therapeutics, Inc. (PTGX)

NASDAQ Global Market · Currency in USD
$138.43 ▼ -1.10 (-0.79%)
At close: Oct 23, 4:00 PM ET. Market closed.
$139.00 ▲ +0.57 (+0.41%)
After hours: Oct 23, 7:36 PM ET

Summary

Previous Close
$139.53
Open
$136.89
Day's Range
$135.00 – $139.57
52 Week Range
$74.03 – $160.81
Volume
409,356
Avg. Volume
712,783
Market Cap
$8.96B
Beta (5Y Monthly)
1.79
PE Ratio (TTM)
113.64
EPS (TTM)
$1.26
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$177.25

Profile: Protagonist Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
141
CEO
Dinesh V. Patel

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $2.50 · Revenue est. $238.48M
DateEst.Actual
Aug 5, 2026$2.23$2.29Beat
May 5, 2026-$0.65$0.05Beat
Feb 25, 2026-$0.53-$0.69Miss
Nov 6, 2025-$0.59-$0.62Miss
Aug 6, 2025-$0.53-$0.55Miss
May 6, 2025-$0.50-$0.19Beat

Analyst view

Consensus price target
$177.25 ▲ +28.0%
Range $165.00 – $190.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on PTGX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.